[Clinical efficacy of cytoflavin in the combined treatment of patients during acute phase of ischemic stroke].
This study investigated efficiency of cytoflavin in combined treatment of acute hemisphere or stem stroke. It included 35 patients aged 40-70 years with the newly diagnosed mild and moderate stroke. The main group comprised 29 patients treated with cytoflavin (10 ml twice daily by i/v drop infusion for 10 days) in addition to basal therapy. Controls (n=15) were given basal therapy alone. All patients were examined on days 1 and 15 for the evaluation of their neurological status, neuropsychological testing, assessment of cognitive function (from the ability to remember 10 words), everyday activities, and quality of life (based on the QOL scale). Evaluation of the neurological status by the NIHSS scale on day 15 after the onset of therapy revealed its positive dynamics. Indicators of functional normalization in groups 1 and 2 were significantly different. Analysis of social and functional activities on day 15 demonstrated a higher Bartel index in patients given cytoflavin. Moreover these patients showed significant improvement of short- and long-term memory as well as the highest health index. The MMSE test did not reveal significant difference between the two groups on day 15 (p > 0.05). It is concluded that cytoflavin therapy significantly improved the health status of the patients. It proved efficacious as regards correction of motor and non-motor symptoms in patients having acute ischemic stroke.